The National Committee for Infections is meeting with the main topic of restoring the measure of the mask in hospitals and accommodation units for people with health problems.

According to ERT, experts are worried after the increase in cases of coronavirus and flu, recorded in recent weeks. It should be noted that scientists express concern and concern for the low turnout regarding the updated vaccine as only one in ten belonging to vulnerable groups has done so.

Coronavirus: Cases on the rise worldwide – What’s up with the JN.1 subvariant — ‘Too early to draw conclusions’

The JN.1 subunit of COVID accounts for 39% to 50% of cases in the United States, the United States Centers for Disease Control and Prevention (CDC) announced on Friday. The agency’s projections lead to the conclusion that it is the most widely circulated subvariant in the US.

CDC: “Too early to know if and how JN.1 will cause hospitalizations”

Theodora Psaltopoulou, Professor of Epidemiology and Preventive Medicine at the Faculty of Medicine of the EKPAthe Biologist Panagiota Zaharakis and the Professor of Epidemiology of the School of Medicine of the EKPA and Vice President of the EODY Dimitris Paraskevis, summarize the latest data.

This is an increase from 15% to 29% of cases in the United States, which the CDC had predicted by December 8. The continued increase suggests that the subvariant is either more contagious or better at evading immune systems than other subunits, the CDC added.

It’s too early to know if and how JN.1 will cause hospitalizations, according to the CDCadding that existing vaccines, tests and treatments still work well against it.

On Tuesday, the World Health Organization classified JN.1 as a “subunit of interest” and said the current indicative The United States Centers for Disease Control and Prevention (CDC) announced on Friday that the JN.1 subunit of COVID accounts for 39% to 50% of cases in United States, according to the organization’s forecasts.

This is an increase from the estimated 15% to 29% of cases in the United States, which the CDC had predicted by December 8.

The CDC reported that the subunit continues to cause an increasing percentage of infections and is now the most widely circulated sub-unit in the country.

Continued growth suggests that the subunit is either more contagious or better in evading immune systems, from other subunits, the CDC added.

It’s too early to know if and how JN.1 will cause an increase in infections or hospitalizations, the CDC said, adding that existing vaccines, tests and treatments still work well against it.

According to a recent publication in the Lancet of Yang et al, the earlier SARS-CoV-2 BA.2.86 subvariant, which was quickly put under surveillance after its emergence, had garnered global attention. Although BA.2.86 did not show a substantial humoral immune evasion and growth advantage compared to the current dominant variants, it did show remarkably high binding affinity to ACE2. This increased binding affinity, combined with its distinct antigenicity, could allow BA.2.86 to accumulate immune-evading mutations during population transmission. With only one additional receptor-binding domain mutation (L455S) compared with its predecessor the BA.2.86, the JN.1 variant quickly became dominant in France.

There appears to be a marked decrease in ACE2 binding affinity in the JN.1 subvariant, indicating that enhanced immune evasion capabilities come at the expense of reduced ACE2 binding.

Considering that the L455 is located primarily in the receptor-binding domain Class 1 antibody epitope, this study further examined the evasion potential of JN.1 in response to eight XBB.1·5 neutralizing class 1 monoclonal antibodies. This mutation effectively compensated for the sensitivity of BA.2.86 to this panel of antibodies. Together, these findings suggest that L455S significantly enhanced the resistance of JN.1 to humoral immunity by compensating for the weakness of BA.2.86 to class 1 antibodies.

In summary, the JN.1, inheriting the antigenic diversity of BA.2.86 and together with the acquisition of L455S, rapidly achieved widespread resistance to class 1, 2 and 3 receptor-binding domain antibodies, and showed higher immune evasion compared to BA.2.86 and other resistant strains such as HV.1 and JD.1·1, at the expense of reduced binding of human ACE2. Such strains could survive and transmit, as their antigenic difference would allow them to target different populations compared to dominant strains and would have the potential to rapidly accumulate highly immune-evasive mutations at the cost of human ACE2 binding abilities.

However, the World Health Organization has maintained the classification of JN.1 as a “subvariant of interest” meaning a low risk to public health, at least up to the current scientific data.